Mabwell presents Phase II trial results for breast cancer drug 9MW2821
October 19, 2026 | 16:13
Biopharmaceutical firm Mabwell scheduled Phase II clinical trial data presentations for its Nectin-4-targeting antibody-drug conjugate 9MW2821 at the European Society for Medical Oncology Congress.
Mobile Version